Effectiveness of Non-pharmacological Interventions in Patients With Cardiovascular Risk Factors in Primary Care
26 de fevereiro de 2018 atualizado por: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Clinical Trial of the Effectiveness of Non-pharmacological Interventions (Physical Activity + ABPM) in Patients With Cardiovascular Risk Factors in Primary Care
The principal objective is analyzed whether a selective intervention no pharmacological (use of ABPM +/- prescription of physical exercise) for cardiovascular risk factors in patients with high cardiovascular risk in primary prevention is associated with a decrease in cardiovascular risk measured using the risk Score tables for countries with a low risk.
It will be independently analized the effectiveness of systematic use of ABPM and the prescription of physical exercise.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Cardiovascular disease continues to be the main cause of death in Western countries, with a very high prevalence (affecting >1 in every 3 adult Americans), and contributes as one of the highest annual healthcare costs. There is still enormous potential for improving prevention although notable efforts have already been made. In the Spanish population, the following cardiovascular risk factors have been identified as being most prevalent: arterial hypertension, dyslipidemia, having a sedentary lifestyle, tobaccoism, obesity and diabetes.
Essential Arterial Hypertension (EAH) is the most prevalent cardiovascular risk factor in the world and the main cause of cardiovascular disease. There are many clinical practice guides which recommend carrying out moderate physical activity to prevent, delay or reduce hypertension, given that the practice of community interventions with physical activity have been efficient.
The indication to perform Itinerant Monitorization blood pressure in the diagnosis of hypertension is included in the latest draft of the clinical practice guideline from NICE, National Institute for Health and Clinical Excellence .
Other cardiovascular risk factor to take into account is dyslipidemia, the prevalence of dyslipidemia is 16.2% in adults aged over 20 years. For this condition, physical activity is also recommended.
When faced with a sedentary lifestyle or physical inactivity two intervention measures are available for reducing its incidence: verbal healthcare advice (taking advantage of the patients visit to the consultation) and the prescription of physical exercise.
Taking into account the interventions mentioned that can be carried out in the face of risk factors, and that a multifactorial intervention is more efficient that individual interventions, the investigators have designed a clinical trial which attempts to improve most of the principal risk factors. The objective is to reduce the cardiovascular risk of patients using a multifactorial intervention on hypertension, dyslipidemia, sedentary lifestyle. The investigators will evaluate the efficiency of a program for official prescriptions for physical exercise compared to structured verbal advice in hypertense patients undergoing treatment and who have another risk factors (dyslipidemia being treated for more than one year or they are smokers), including action to improve the treatment adaptation for the hypertension (ABPM).
Tipo de estudo
Intervencional
Inscrição (Real)
3656
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Comunidad Autonoma De La Region De Murcia
-
Murcia, Comunidad Autonoma De La Region De Murcia, Espanha, 30003
- Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
35 anos a 65 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Undergoing treatment with at least one hypertense drug due to HTA and at least one hypolipemiant drug prescribed due to hypercholesterolemia, or other risk factor. The treatment should have a minimum duration time of 12 months prior to inclusion in the study.
- Patient in Primary Prevention.
- Finding oneself in the sedentary lifestyle category or through activation of the simplified active questionnaire of physical activity extracted from the Lipid Research Clinics prevalence Study
Exclusion Criteria:
- Serious or terminal diseases.
- Diagnosis of ischemic and/or cerebrovascular cardiopathy.
- Patients with a limiting pathology which prevents physical exercise being performed.
- Serious mental illnesses: Psychosis, Major depressive disorder, Neurosis.
- Diabetes mellitus.
- Patients with limiting pathology preventing them from carrying out physical exercise.
- Serious mental diseases: Psychosis, Major depresive disorder, Neurosis.
- Pregnancy
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Control group: no intervention
Only the normal practise
|
|
|
Experimental: therapeutic exercise
In this group the intervention is the prescription of physical activity.
The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
|
The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
physical activity programmed by an instructor in patient with high risk of cardiovascular.
|
|
Experimental: ABPM
In this group the arterial pressure is evaluated with ABPM.
|
Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm.
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
|
|
Experimental: therapeutic exercise + ABPM
|
The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
physical activity programmed by an instructor in patient with high risk of cardiovascular.
Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm.
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cardiovascular risk .
Prazo: Every 3 months , up to 12 months.
|
Tables for countries with low cardiovascular risk
|
Every 3 months , up to 12 months.
|
|
Systolic arterial tension
Prazo: Every 3 months , up to 12 months
|
blood pressure
|
Every 3 months , up to 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
diastolic arterial tension
Prazo: Every 3 months , up to 12 months
|
blood pressure
|
Every 3 months , up to 12 months
|
|
Cholesterol levels.
Prazo: Every 3 months , up to 12 months
|
blood levels.
|
Every 3 months , up to 12 months
|
|
Physical Activity
Prazo: Every 3 months , up to 12 months
|
International Physical Activity Questionniare (IPAQ) 600-3000 MET (METs are multiples of the resting metabolic rate
|
Every 3 months , up to 12 months
|
|
Pharmacological treatment.
Prazo: Every 3 months , up to 12 months
|
Number of antihypertensive and hypolipemiant drug and dose.
|
Every 3 months , up to 12 months
|
|
EUROFIT battery
Prazo: Every 3 months , up to 12 months
|
Score obtained
|
Every 3 months , up to 12 months
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Investigadores
- Investigador principal: A Lopez-santiago, MD, Consejeria de sanidad y consumo, Direccion general de planificacion, ordenacion sanitaria y farmaceutica e investigacion.
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15. Erratum In: Circulation. 2011 Feb 15;123(6):e240. Circulation. 2011 Oct 18;124(16):e426.
- Medrano MJ, Cerrato E, Boix R, Delgado-Rodriguez M. [Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies]. Med Clin (Barc). 2005 Apr 30;124(16):606-12. doi: 10.1157/13074389. Spanish.
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993 Feb;16(2):434-44. doi: 10.2337/diacare.16.2.434.
- Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002 Nov 2;360(9343):1347-60. doi: 10.1016/S0140-6736(02)11403-6.
- Martin-Baranera M, Campo C, Coca A, de la Figuera M, Marin R, Ruilope LM; en representacion del Grupo de Investigadores DICOPRESS. [Stratification and degree of control of cardiovascular risk factors in hypertensive Spanish population. Results of the DICOPRESS study]. Med Clin (Barc). 2007 Jul 14;129(7):247-51. doi: 10.1157/13108347. Spanish.
- Sierra C, De la Sierra A, Sobrino J, Segura J, Banegas JR, Gorostidi M, Ruilope LM; en representacion de los Investigadores del Registro Nacional de MAPA. Sociedad Espanola de Hipertension-Liga Espanola para la Lucha contra la Hipertension Arterial (SEH-LELHA). [Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]. Med Clin (Barc). 2007 Jun 2;129(1):1-5. doi: 10.1157/13106673. Spanish.
- Hypertension: clinical management of primary hypertension in adults NICE guideline. Draft for consultation, February 2011. access (29/3/2011: http://www.nice.org.uk/nicemedia/live/12167/53225/53225.pdf).
- Lee LL, Arthur A, Avis M. Evaluating a community-based walking intervention for hypertensive older people in Taiwan: a randomized controlled trial. Prev Med. 2007 Feb;44(2):160-6. doi: 10.1016/j.ypmed.2006.09.001. Epub 2006 Oct 20.
- Elley CR, Garrett S, Rose SB, O'Dea D, Lawton BA, Moyes SA, Dowell AC. Cost-effectiveness of exercise on prescription with telephone support among women in general practice over 2 years. Br J Sports Med. 2011 Dec;45(15):1223-9. doi: 10.1136/bjsm.2010.072439. Epub 2010 Nov 16.
- Grandes G, Sanchez A, Sanchez-Pinilla RO, Torcal J, Montoya I, Lizarraga K, Serra J; PEPAF Group. Effectiveness of physical activity advice and prescription by physicians in routine primary care: a cluster randomized trial. Arch Intern Med. 2009 Apr 13;169(7):694-701. doi: 10.1001/archinternmed.2009.23.
- Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002 Apr 2;136(7):493-503. doi: 10.7326/0003-4819-136-7-200204020-00006.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de dezembro de 2011
Conclusão Primária (Real)
1 de setembro de 2016
Conclusão do estudo (Real)
1 de setembro de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
22 de junho de 2011
Enviado pela primeira vez que atendeu aos critérios de CQ
26 de fevereiro de 2018
Primeira postagem (Real)
2 de março de 2018
Atualizações de registro de estudo
Última Atualização Postada (Real)
2 de março de 2018
Última atualização enviada que atendeu aos critérios de controle de qualidade
26 de fevereiro de 2018
Última verificação
1 de dezembro de 2017
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ACTIVA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença cardiovascular
-
Mayo ClinicConcluídoRisco Cardiovascular | Prevenção CardiovascularEstados Unidos
-
Fu Jen Catholic UniversityRecrutamentoDoença cardiovascular | Cirurgia CardiovascularTaiwan
-
Alliance For Medical Research in AfricaInstitut Pasteur de DakarAtivo, não recrutandoCâncer | Mortalidade | Cardiovascular | Doença cardiovascularSenegal
-
Martha BiddleInscrevendo-se por conviteRisco Cardiovascular | Redução do Risco CardiovascularEstados Unidos
-
University of DelawareAtivo, não recrutandoFator de Risco Cardiovascular | Saúde cardiovascularEstados Unidos
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecrutamentoCardiovascular | Saúde cardiovascular | Risco Cardiovascular (CV) | Fatores de risco para doenças cardiovasculares (DCV)Estados Unidos
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS e outros colaboradoresRecrutamentoRisco Cardiovascular | Risco cardiovascular genéticoItália
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)ConcluídoDoenças cardiovasculares | Fator de Risco Cardiovascular | Saúde cardiovascularEstados Unidos
-
Hospital Mutua de TerrassaConcluídoDoença cardiovascular | Fator de Risco CardiovascularEspanha
-
Oregon Health and Science UniversityConcluídoDoença cardiovascular | Fatores de Risco CardiovascularEstados Unidos
Ensaios clínicos em therapeutic exercise
-
Sultan Abdulhamid Han Training and Research Hospital...ConcluídoTremor | DOENÇA DE PARKINSON (distúrbio) | Tremor Associado à Doença de Parkinson Tremor DominanteTurquia (Türkiye)
-
Kessler FoundationBrainQ Technologies Ltd.Ainda não está recrutando
-
Universitätsklinikum Hamburg-EppendorfGerman Research FoundationConcluídoDerrame | Envelhecimento | AfasiaAlemanha
-
University Hospital for Infectious Diseases, CroatiaDesconhecidoCOVID-19 | Pneumonia graveCroácia
-
Johnson & Johnson Pharmaceutical Research & Development...Concluído
-
Universitätsklinikum Hamburg-EppendorfGerman Research Foundation; University Hospital TuebingenConcluído